Skip to main content

Quest Diagnostics Value Stock - Dividend - Research Selection

Quest diagnostics

ISIN: US74834L1008 , WKN: 904533

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company\'s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million

2026-09-08
J. E. Davis disposed of 8% of his direct equity stake under a pre-planned Rule 10b5-1 trading arrangement, retaining $28.9 million in company stock.

Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?

2026-09-05
Testing for Alzheimer’s-related brain changes has traditionally depended on procedures that can be expensive, invasive, or difficult to access. Roche Holding AG and Eli Lilly and Company (NYSE:LLY) may now have a simpler way to help physicians evaluate certain patients. The FDA has cleared Elecsys pTau217, which is a blood test that helps identify whether […]

Clinical Laboratory Services Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)

2026-09-04
The global clinical laboratory services market was valued at USD 274.6 billion in 2025 and is forecast to reach USD 468.2 billion by 2036, rising from USD 298.4 billion in 2026 at a 4.6% CAGR. Growth is driven by chronic diseases, preventive healthcare, molecular diagnostics, genomic testing, precision medicine, laboratory automation, AI-enabled diagnostics, and at-home testing. North America leads, while Asia-Pacific is set for the fastest growth. The report analyzes key segments, regions, oppo

Quest’s Expanded Alzheimer’s and Wellness Testing Push Might Change The Case For Investing In DGX

2026-09-04
In recent months, Renalytix PLC, Humanity Health Inc., and Quest Diagnostics have announced new collaborations and product launches, including a nationwide kidneyintelX.dkd testing program, a Humanity Biological Age wellness add-on on questhealth.com, and expanded AD-Detect blood-based Alzheimer’s tests accessible through Quest’s U.S. collection network. Together, these moves highlight Quest’s push to deepen its role in advanced kidney, brain health, and consumer-oriented wellness testing...

Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?

2026-09-03
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Market Shocks Are Not Where Hims & Hers Health Stock Has Fallen Furthest

2026-08-31
Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.

Chemed (CHE) Up 1.7% Since Last Earnings Report: Can It Continue?

2026-08-27
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Quest Diagnostics Stock: Is Wall Street Bullish or Bearish?

2026-08-25
While Quest Diagnostics has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference

2026-08-25
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026, at 10:50 a.m. Eastern Time.

Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com

2026-08-25
Humanity Health Inc. ("Humanity"), the longevity science company, and Quest Diagnostics (NYSE: DGX) today announced that Humanity Biological Age, Humanity's scientifically validated model for measuring biological age from biomarker lab test results, is now available in the United States for the first time through questhealth.com, Quest's consumer-initiated testing platform.